AzTrials
AzTrials

Intracranial Pressure IncreaseNCT03418753

Non-invasive Diagnostic for Assessing Elevated Intracranial Pressure

An observational study of Intracranial Pressure Increase, run by Oculogica, Inc. at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The study is a prospective, multi-center, non-randomized, open label observational study. The objective of this study is to compare the accuracy of the EyeBOX to a clinical diagnosis of abnormal ICP as determined by an external ventriculostomy drain (EVD) or ventriculostomy catheter. Read more about this study

Who is it for?
Ages 4 to 70 years
Conditions the study is for
Intracranial Pressure Increase
What is being tested?
EyeBOX for ICP
How many people
60 participants
Where
3 sitesUnited States
Study dates
10 May 2018to 10 May 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 70 years
  • All sexes
  • Child, Adult, Older adult

Study population: The study will enroll pediatric and adult patients with abnormal ICP. Subjects who meet all of the inclusion criteria and none of the exclusion criteria will be considered for enrollment into the study. There will be no enrollment restrictions based on race, ethnic origin, gender, or pregnancy status and efforts will be made to ensure that the benefits and burdens of research participation are distributed in an equitable manner. Subjects must require ICP monitoring for clinical indications. At the time when eye tracking is performed all patients must be awake with spontaneous eye opening.

Who may be able to join

  • Provide written informed consent.
  • Require placement of an ICP monitor or ventriculostomy catheter for clinical purposes.
  • Be between the ages of 4 and 70 years old.
  • Have baseline vision correctable to within 20/500 bilaterally.
  • Have no prior history of ocular dysmotility.
  • Be awake with spontaneous eye opening at the time when eye tracking is performed.

Who cannot join

  • Have a prior history of strabismus, diplopia, or palsy of CN-III, IV or VI.
  • Be blind (no light perception), have missing eyes, be unable to open their eyes.
  • Have a prior history of ocular motility dysfunction.
  • Have had extensive prior eye surgery.
  • Have any physical or mental injury or baseline disability rendering task completion difficult.
  • Be intoxicated or have blood alcohol level greater than 0.2.
  • Be a prisoner or in the company of a police officer or law enforcement officer pending arrest.

Trial locations and contacts

3 sites in 1 country.

United States3 sites
  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104

  • Mayo Clinic

    Rochester, Minnesota, 55905

Other trials in United States

About this study

The study is a prospective, multi-center, non-randomized, open label observational study. The objective of this study is to compare the accuracy of the EyeBOX to a clinical diagnosis of abnormal ICP as determined by an external ventriculostomy drain (EVD) or ventriculostomy catheter.

Being tested
EyeBOX for ICP
Keywords
noninvasive diagnosis
Medical subject headings
Intracranial Hypertension

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EyeBOX for ICPDiagnostic test

    non-invasive ICP Score algorithm using eye-tracking data from the EyeBOX(TM) device, which tracks the movement of the pupils over time

Study groups in NCT03418753
Study groupRoleWhat they receive
singlesubjects with abnormal intracranial pressure
Receives: Diagnostic Test: EyeBOX for ICP

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sensitivity and Specificity

    EyeBOX assessment of abnormal ICP relative to invasive intracranial pressure monitor

    Measured: from time of enrollment through the period that ICP monitoring is required for clinical purposes up to 104 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Feb 2018
  2. Study start10 May 2018
  3. Primary completion10 May 2023
  4. Study completion10 May 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03418753
Sponsor's protocol ID
ICP001
Status last verified
Aug 2023
First submitted
17 Jan 2018
Last updated
7 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Publications

  • Kolecki R, Dammavalam V, Bin Zahid A, Hubbard M, Choudhry O, Reyes M, Han B, Wang T, Papas PV, Adem A, North E, Gilbertson DT, Kondziolka D, Huang JH, Huang PP, Samadani U. Elevated intracranial pressure and reversible eye-tracking changes detected while viewing a film clip. J Neurosurg. 2018 Mar;128(3):811-818. doi: 10.3171/2016.12.JNS161265. Epub 2017 Jun 2.

    PubMed 28574312

Questions about this trial

What is this clinical trial studying?

An observational study of Intracranial Pressure Increase, run by Oculogica, Inc. at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sensitivity and Specificity (time frame: from time of enrollment through the period that ICP monitoring is required for clinical purposes up to 104 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03418753, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in